Hong Kong Beverage Stock News

In the past few days, JAMA Dermatology published Phase II data showing InnoCare Pharma’s TYK2 inhibitor soficitinib delivered encouraging efficacy and a favorable safety profile in patients with moderate-to-severe atopic dermatitis, while the company also completed enrollment of 579 patients for its Phase III trial in the same indication. This combination of peer-reviewed validation and late-stage trial readiness positions soficitinib as a potentially important entrant in the competitive...

Hang Lung Properties has reported its full-year 2025 results, with sales of HK$9,950 million and net income of HK$1,806 million, and the board has recommended a final cash dividend of HK$0.40 per share for the year ending December 31, 2026, payable on June 15, 2026. The proposed final dividend, coming alongside lower sales and earnings compared with the prior year, highlights management’s commitment to cash returns even as profitability softened. We’ll now look at how the earnings decline...

In past guidance for 2025, Air China Limited said it expects to post a net loss of about RMB 1.30 billion to RMB 1.90 billion, with an even larger loss of roughly RMB 1.90 billion to RMB 2.70 billion after excluding non-recurring items. This outlook highlights how underlying operations, once one-off gains and losses are stripped out, could weigh more heavily on Air China’s financial performance. Next, we’ll examine how this projected 2025 loss, particularly after excluding non-recurring...

Aluminum Corporation of China (SEHK:2600) reported a reshuffle in its company secretary roles, with the previous company secretary resigning. The board appointed two joint company secretaries: long serving executive Ms. Zhu Dan and corporate governance specialist Mr. Chow Tsz Ho. The move brings together internal operational experience and external compliance expertise in the core governance function. For investors watching Aluminum Corporation of China at HK$13.85, this governance change...

East Buy Holding Limited recently reported half-year results for the period ended November 30, 2025, with sales of CNY 2,311.63 million and net income of CNY 238.97 million, reversing a net loss in the same period a year earlier. The move from a basic loss per share of CNY 0.09 to basic earnings per share of CNY 0.23 highlights a meaningful operational turnaround and improved profitability from continuing operations. We will now examine how this swing back to profitability shapes East Buy...

If you are wondering whether CK Hutchison Holdings is attractively priced right now or if the recent excitement has already been baked into the share price, this article walks you through that question step by step. The stock recently closed at HK$63.25, with returns of 0.7% over 7 days, 19.5% over 30 days, 17.1% year to date, 69.3% over 1 year, 51.7% over 3 years, and 54.6% over 5 years. This naturally raises questions about how much value is still on the table. These moves are set against...

Huishang Bank (SEHK:3698) has proposed an interim dividend of CN¥1.87 per 10 shares for the six months to 30 June 2025, subject to shareholder approval scheduled for 2 February 2026. See our latest analysis for Huishang Bank. At a share price of HK$3.45, Huishang Bank has seen a 7.81% 30 day share price return and a 48.60% 1 year total shareholder return. This suggests recent momentum has been positive despite a small 1 day pullback, with the proposed interim dividend adding another focal...

AstraZeneca recently announced a new collaboration with CSPC Pharmaceutical Group to advance eight next-generation obesity and type 2 diabetes therapies, anchored by CSPC’s AI-driven peptide discovery and once-monthly LiquidGel injection platform, with AstraZeneca receiving worldwide rights outside China to CSPC’s once-monthly injectable weight management portfolio. The agreement includes an upfront payment of US$1.20 billion and up to US$3.50 billion in potential development and regulatory...

Hong Kong Exchanges and Clearing Limited recently issued earnings guidance for the full year 2025, forecasting net profit attributable to shareholders between RMB 147.99 million and RMB 180.17 million, with profit after excluding non-recurring items expected between RMB 29.19 million and RMB 39.50 million. This guidance points to a significant reduction in prior losses and highlights how non-recurring items still play a meaningful role in the company’s reported profitability. We will now...

BYD is accelerating its global expansion, reassessing its India plans in response to import rules and rising local EV demand. In Mexico, the company is reacting to higher tariffs on Chinese manufacturers with regional production and tighter inventory planning. BYD is investing in Vietnam through a new battery joint venture aimed at supporting local supply and vehicle manufacturing capabilities. Across Europe, BYD reports that its EV sales are outpacing petrol vehicles, reflecting gains...

Chow Tai Fook Jewellery Group has opened a key store in Bangkok’s Siam Paragon and named Chinese actor Yang Yang as Global Brand Ambassador, while outlining past and upcoming international expansion into Australia, Canada and the Middle East as part of its ongoing brand transformation. Beyond adding another high-end location, the group is using Chinese craftsmanship, localised collections and celebrity-driven storytelling to reposition itself as a modern expression of Chinese luxury for...

As global markets navigate a volatile start to the year, with U.S. indices experiencing fluctuations due to geopolitical tensions and revised economic forecasts, investors are closely monitoring opportunities in dividend stocks. In such uncertain times, dividend-paying stocks can offer a measure of stability and income potential, making them an attractive option for those seeking to balance growth with consistent returns amidst market turbulence.

Key Insights PICC Property and Casualty's significant public companies ownership suggests that the key decisions are...

Shanghai Conant Optical Co., Ltd. recently issued consolidated earnings guidance for 2025, indicating that net profit attributable to shareholders is expected to rise by at least 30% year-on-year, supported by stronger sales of high-index 1.74 lenses and other multifunctional products, greater economies of scale and automation, and lower financing costs through an optimized capital structure. This guidance highlights how product mix upgrades toward more advanced lenses, combined with...

China Reinsurance (Group) Corporation recently obtained regulatory approval for amendments to its Articles of Association, abolishing its Board of Supervisors and transferring those oversight responsibilities to the board’s audit committee with immediate effect. This shift consolidates supervisory powers within a single board-level committee, marking a material change in how the group structures internal control and corporate oversight. We will now examine how consolidating supervisory...

Sun Hung Kai (SEHK:86) has been active on the funding side. It recently completed a tender offer for existing US dollar notes and issued new 6.75% guaranteed bonds due 2029 totaling $250 million. See our latest analysis for Sun Hung Kai. These funding moves come after a strong run in the shares, with a 9.5% 1 month share price return and a 13.47% 3 month share price return. The 1 year total shareholder return of 72.11% and 5 year total shareholder return of 104.88% point to momentum that has...

CTF Services (SEHK:659) is in focus after its insurance arm, CTF Life, released its first standalone ESG Disclosure Report. The report outlines plans around family wellness, ESG focused investing, and governance and risk management. See our latest analysis for CTF Services. The ESG report lands at a time when momentum in CTF Services' shares has been picking up, with a 1 month share price return of 21.20% and a 1 year total shareholder return of 53.23%. This suggests investors are reacting to...

GenScript Biotech (SEHK:1548) recently hosted a major global forum focused on practical applications of artificial intelligence in biopharma and drug discovery. The company is also working with Latent Labs as a wet lab partner to rapidly test and validate AI generated molecules for potential therapeutics. For you as an investor or industry follower, this update highlights how GenScript Biotech is positioning itself at the intersection of AI tools and biopharma research. The company is known...

Renewed interest in Industrial and Commercial Bank of China (SEHK:1398) has picked up after-hours, with trading volume in Hong Kong rising alongside supportive economic data that has drawn investors back toward large-cap Chinese banks. See our latest analysis for Industrial and Commercial Bank of China. At a latest share price of HK$6.64, Industrial and Commercial Bank of China has seen a 7.62% 7 day share price return and a 10.30% 90 day share price return. Its 1 year total shareholder...

Infinity Development Holdings Company Limited ( HKG:640 ) is about to trade ex-dividend in the next 2 days. The...

InSilico Medicine Cayman TopCo (SEHK:3696) has agreed a major partnership with Qilu Pharmaceutical to co-develop small molecule drugs for cardiometabolic diseases using its Pharma.AI platform. The company is also reporting progress and fresh licensing activity around its ISM8969 program, which targets neurodegenerative disorders. Together, these updates mark a shift from a primarily software licensing approach toward more hands-on, co-development work in drug discovery. For you as an...

CSSC (Hong Kong) Shipping Company Limited previously announced a fixed-income offering of HK$2.34 billion in 0.75% subordinated, unsubordinated fixed-rate bonds due January 28, 2031. This sizable subordinated bond issue highlights the company’s focus on raising long-term funding through debt markets while preserving existing equity ownership. We will now examine how this HK$2.34 billion subordinated bond issuance shapes CSSC (Hong Kong) Shipping’s broader investment narrative and...

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 12x, you may consider...

In January 2026, Guotai Junan International Holdings Limited issued earnings guidance for 2025, projecting net profit of between HK$1,280 million and HK$1,380 million, a very large percentage increase from the approximately HK$351 million reported for 2024. The company attributed this sharp profit uplift to broad-based revenue gains across corporate finance, wealth management, asset management, and trading and investment, with especially strong contributions from equity capital markets and...